VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives $0.95 Average Price Target from Brokerages

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have earned a consensus rating of “Reduce” from the five ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $0.95.

Several brokerages have weighed in on VTGN. Weiss Ratings reiterated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Stifel Nicolaus cut shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price target for the company. in a research report on Wednesday, December 17th. Maxim Group restated a “hold” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Finally, William Blair reiterated a “market perform” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th.

VistaGen Therapeutics Stock Down 1.1%

VistaGen Therapeutics stock opened at $0.66 on Friday. The firm has a fifty day simple moving average of $2.66 and a two-hundred day simple moving average of $3.07. VistaGen Therapeutics has a twelve month low of $0.63 and a twelve month high of $5.14. The company has a market capitalization of $26.22 million, a PE ratio of -0.35 and a beta of 0.31.

VistaGen Therapeutics (NASDAQ:VTGN) last released its earnings results on Thursday, November 13th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The firm had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.16 million. As a group, equities analysts expect that VistaGen Therapeutics will post -1.77 earnings per share for the current fiscal year.

Key Stories Impacting VistaGen Therapeutics

Here are the key news stories impacting VistaGen Therapeutics this week:

• Positive Sentiment: Brokerage note sets a new price target of $0.95, which implies upside relative to current trading levels. Read More.
• Neutral Sentiment: Robbins LLP reminds investors that a class action has been filed covering Apr. 1, 2024–Dec. 16, 2025; this is a notice to potential class members rather than a new allegation. Read More.
• Negative Sentiment: Rosen Law Firm seeks lead plaintiffs and has filed/announced a securities class action covering the same class period — increasing legal attention and potential damages exposure. Read More.
• Negative Sentiment: Holzer & Holzer and other firms allege defendants made false or misleading statements and/or omitted material risks related to the PALISADE‑3 fasedienol trial — these specific allegations heighten downside risk if plaintiffs prevail. Read More.
• Negative Sentiment: Multiple other firms (Bernstein Liebhard, Gainey McKenna & Egleston, Levi & Korsinsky, Faruqi & Faruqi, Schall Law Firm and others) have filed notices, investor alerts or suits — the volume of filings amplifies reputational and legal risk. Read More.
• Negative Sentiment: Analyst price‑target revisions include a significant cut (reported down ~48.6% to $3.80), signaling reduced near‑term expectations and possible re‑rating pressure. Read More.

Institutional Trading of VistaGen Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Two Sigma Investments LP lifted its position in shares of VistaGen Therapeutics by 223.5% during the 3rd quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock valued at $1,027,000 after buying an additional 199,958 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of VistaGen Therapeutics during the second quarter worth about $190,000. Stempoint Capital LP raised its stake in VistaGen Therapeutics by 2.0% during the 2nd quarter. Stempoint Capital LP now owns 2,413,254 shares of the company’s stock valued at $4,827,000 after purchasing an additional 46,700 shares during the period. AdvisorShares Investments LLC lifted its holdings in VistaGen Therapeutics by 27.7% in the 2nd quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company’s stock worth $406,000 after purchasing an additional 44,000 shares in the last quarter. Finally, Occudo Quantitative Strategies LP bought a new position in VistaGen Therapeutics in the 3rd quarter worth approximately $152,000. 78.39% of the stock is currently owned by institutional investors.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.